Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Teva
McKesson
Daiichi Sankyo
Covington
Fish and Richardson
Cipla
Moodys
Julphar
Citi

Generated: October 17, 2017

DrugPatentWatch Database Preview

DEPOMED INC Company Profile

« Back to Dashboard

What is the competitive landscape for DEPOMED INC, and what generic alternatives to DEPOMED INC drugs are available?

DEPOMED INC has eight approved drugs.

There are thirty-six US patents protecting DEPOMED INC drugs.

There are five hundred and ten patent family members on DEPOMED INC drugs in fifty-one countries and twenty-three supplementary protection certificates in ten countries.

Summary for Applicant: DEPOMED INC

International Patents:510
US Patents:36
Tradenames:7
Ingredients:5
NDAs:8
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Depomed Inc
GRALISE
gabapentin
TABLET;ORAL022544-002Jan 28, 2011BXRXYesYes► Subscribe► SubscribeY ► Subscribe
Depomed Inc
GRALISE
gabapentin
TABLET;ORAL022544-001Jan 28, 2011BXRXYesYes► Subscribe► SubscribeY ► Subscribe
Depomed Inc
NUCYNTA
tapentadol hydrochloride
TABLET;ORAL022304-002Nov 20, 2008RXYesNo► Subscribe► SubscribeYY ► Subscribe
Depomed Inc
ZIPSOR
diclofenac potassium
CAPSULE;ORAL022202-001Jun 16, 2009ABRXYesYes► Subscribe► Subscribe ► Subscribe
Depomed Inc
NUCYNTA ER
tapentadol hydrochloride
TABLET, EXTENDED RELEASE;ORAL200533-004Aug 25, 2011RXYesNo► Subscribe► SubscribeYY ► Subscribe
Depomed Inc
NUCYNTA ER
tapentadol hydrochloride
TABLET, EXTENDED RELEASE;ORAL200533-002Aug 25, 2011RXYesNo► Subscribe► SubscribeY ► Subscribe
Depomed Inc
GRALISE
gabapentin
TABLET;ORAL022544-001Jan 28, 2011BXRXYesYes► Subscribe► SubscribeY ► Subscribe
Depomed Inc
NUCYNTA ER
tapentadol hydrochloride
TABLET, EXTENDED RELEASE;ORAL200533-005Aug 25, 2011RXYesYes► Subscribe► SubscribeYY ► Subscribe
Depomed Inc
NUCYNTA ER
tapentadol hydrochloride
TABLET, EXTENDED RELEASE;ORAL200533-003Aug 25, 2011RXYesNo► Subscribe► SubscribeY ► Subscribe
Depomed Inc
LAZANDA
fentanyl citrate
SPRAY, METERED;NASAL022569-001Jun 30, 2011RXYesNo► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Depomed Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Depomed Inc
NUCYNTA
tapentadol hydrochloride
TABLET;ORAL022304-001Nov 20, 2008► Subscribe► Subscribe
Depomed Inc
PROQUIN XR
ciprofloxacin hydrochloride
TABLET, EXTENDED RELEASE;ORAL021744-001May 19, 2005► Subscribe► Subscribe
Depomed Inc
PROQUIN XR
ciprofloxacin hydrochloride
TABLET, EXTENDED RELEASE;ORAL021744-001May 19, 2005► Subscribe► Subscribe
Depomed Inc
CAMBIA
diclofenac potassium
FOR SOLUTION;ORAL022165-001Jun 17, 2009► Subscribe► Subscribe
Depomed Inc
GRALISE
gabapentin
TABLET;ORAL022544-002Jan 28, 2011► Subscribe► Subscribe
Depomed Inc
NUCYNTA ER
tapentadol hydrochloride
TABLET, EXTENDED RELEASE;ORAL200533-003Aug 25, 2011► Subscribe► Subscribe
Depomed Inc
GRALISE
gabapentin
TABLET;ORAL022544-001Jan 28, 2011► Subscribe► Subscribe
Depomed Inc
NUCYNTA ER
tapentadol hydrochloride
TABLET, EXTENDED RELEASE;ORAL200533-002Aug 25, 2011► Subscribe► Subscribe
Depomed Inc
NUCYNTA ER
tapentadol hydrochloride
TABLET, EXTENDED RELEASE;ORAL200533-004Aug 25, 2011► Subscribe► Subscribe
Depomed Inc
NUCYNTA
tapentadol hydrochloride
SOLUTION;ORAL203794-001Oct 15, 2012► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for DEPOMED INC drugs

Drugname Dosage Strength Tradename Submissiondate
tapentadol
Oral Solution20 mg/mL
NUCYNTA
12/30/2013
tapentadol
Oral Solution20 mg/mL
NUCYNTA
12/20/2013
tapentadol hydrochloride
Tabletsx50 mg, 75 mg, and 100 mg
NUCYNTA
11/20/2012
tapentadol hydrochloride
Extended-release Tablets50 mg, 100 mg, 150 mg, 200 mg, and 250 mg
NUCYNTA ER
11/20/2012
diclofenac potassium
Capsules25 mg
ZIPSOR
11/14/2012
gabapentin
Tablets300 mg and 600 mg
GRALISE
10/31/2011
diclofenac
Potassium Oral Solution (Sachet)50 mg
CAMBIA
1/24/2011

Non-Orange Book Patents for Depomed Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,750,244 Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases► Subscribe
8,580,303Gastric retained gabapentin dosage form► Subscribe
8,475,813Methods of treatment using a gastric retained gabapentin dosage► Subscribe
8,409,613Gastric retained gabapentin dosage form► Subscribe
8,802,157Methods of treatment using a gastric retained gabapentin dosage form► Subscribe
6,017,965 Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases► Subscribe
7,687,542Rapidly bioavailable tablet and capsule formulations of diclofenac► Subscribe
8,440,232Methods of treatment using a gastric retained gabapentin dosage► Subscribe
9,629,807Abuse-proofed dosage form► Subscribe
7,612,112Methods of treatment using a gastric retained gabapentin dosage► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Depomed Inc Drugs

Country Document Number Estimated Expiration
South Korea20120104199► Subscribe
Malaysia114889► Subscribe
South Korea20030023876► Subscribe
Taiwan200800155► Subscribe
Japan2002509103► Subscribe
Cyprus1115455► Subscribe
Denmark1439825► Subscribe
MexicoPA02012614► Subscribe
South Korea100364465► Subscribe
Israel185018► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Depomed Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2011007,C0693475Lithuania► SubscribePRODUCT NAME: TAPENTADOLUM; NAT. REGISTRATION NO/DATE: LT/1/10/2341/001 - LT/1/10/2341/66, 2011 02 19; LT/1/10/2342/001 - LT/1/10/2342/110 20110219; FIRST REGISTRATION: 75043.00.00 - 75048.00.00, 2010 08 19; 76261.00.00 - 76270.00.00 20100819
00522Netherlands► SubscribePRODUCT NAME: FENTANYL EN DOSERINGSAPPLICATOR; REG. NO/DATE: EU/2/11/127/001 20111006
11/010Ireland► SubscribePRODUCT NAME: TAPENTADOL IN BASIC FORM OR IN THE FORM OF A SALT OF A PHYSIOLOGICALLY COMPATIBLE ACID, ESPECIALLY TAPENTADOL HYDROCHLORIDE; NAT REGISTRATION NO/DATE: PA1189/007/001-008 20101221; FIRST REGISTRATION NO/DATE: PA1189/008/001-008 21/12/2010 GERMANY 75043.00.00 75044.00.00 75045.00.00 19/08/2010 GERMANY 76261.00.00 76262.00.00 76263.00.00 76264.00.00 76265.00.00 19/08/2010 GERMANY 75046.00.00 75047.00.00 75048.00.00 19/08/2010 GERMANY 76266.00.00 76267.00.00 76268.00.0076269.00.00 76270.00.00 20100819
00523Netherlands► SubscribePRODUCT NAME: FENTANYL; REGISTRATION NO/DATE: EU/2/11/127/001 20111006
C/GB12/058United Kingdom► SubscribePRODUCT NAME: A COMBINATION OF CIPROFLOXACIN AND DEXAMETHASONE, PREFERABLY CIPROFLOXACIN HYDROCHLORIDE AND DEXAMETHASONE; REGISTERED: DK DE/11/3337/001/DC 20120808; UK PL000649/0381-0001 20121003
2011000009Germany► SubscribePRODUCT NAME: FENTANYL IN ALLEN DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORMEN; REGISTRATION NO/DATE: EU/1/10/644/001-004 20100831
2014 00016Denmark► SubscribePRODUCT NAME: FENTANYL I EN HVILKEN SOM HELST AF DE FORMER, DER ER BESKYTTET AF GRUNDPATENTET; REG. NO/DATE: EU/1/10/644/001-006 20100831
2006000022Germany► SubscribePRODUCT NAME: TRANSDERMAL IONTOPHORETISCH VERABREICHTES FENTANYL-HYDROCHLORID; REGISTRATION NO/DATE: EU/1/05/326/001 20060126
00541Netherlands► SubscribePRODUCT NAME: TAPENTADOL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, IN HET BIJZONDER TAPENTADOL HYDROCHLORIDE; NAT. REGISTRATION NO/DATE: RVG 110721-110724 RVG 110728-110731 20120316; FIRST REGISTRATION: DE 75043.00.00 - 75045.00.00, 75046.00.00, 76261.00.00 - 76270.00.00 20120819
C/GB06/022United Kingdom► SubscribePRODUCT NAME: FENTANYL HYDROCHLORIDE; REGISTERED: UK EU/1/05/326/001 20060124
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Merck
McKinsey
Healthtrust
AstraZeneca
Medtronic
Julphar
Covington
Teva
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot